60 Gracechurch Street
6th Floor
London EC3V 0HR
United Kingdom
https://www.n4pharma.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 5
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Nigel James Theobald | Founder, CEO & Executive Director | 82,5k | N/D | 1964 |
Dr. David Templeton | Executive Director & Technical Director | 49,5k | N/D | 1952 |
Mr. Luke Sebastian Cairns | Executive Director | 44k | N/D | 1978 |
Rob Harris | Head of CMC Development | N/D | N/D | N/D |
Dr. Andrew Leishman | Consultant | N/D | N/D | N/D |
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.
L'ISS Governance QualityScore di N4 Pharma Plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.